Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions
Executive Summary
Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.
You may also be interested in...
ICER And The VA: Match Made in Heaven?
Institute for Clinical and Economic Review partners with the US Department of Veterans Affairs to support the agency's approach to negotiating and contracting for prescription drugs.
Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.
Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.